The competing PIV cases
Last December, a PIV case involving several ANDA filers concluded its trial in Delaware involving Tecfidera®(dimethyl fumarate). A few months later in West Virginia, a trial in a PIV case involving the product’s 8,399,514 patent concluded against Mylan. Both cases involved the same product, same patent, and same defense – lack of written description. The cases involved similar witnesses and the same legal arguments.
In June, the District Court in West Virginia issued its ruling. It found that several claims of the ‘514 patent are invalid for lack of written description which basically means that the patent language is too broad and vague. As such, the patent is invalid. The Delaware court has not yet issued its trial decision.
However, the West Virginia decision leaves a question for the Delaware District Court: now what? Should the Delaware judge accept the decision of the West Virginia judge or issue a separate decision, perhaps one that draws a different conclusion? It asked the parties in its case what it should do.
The patent holder Biogen claimed that the West Virginia case was “wrongly decided.” It stated that the Delaware judge should render a different decision and find the patent valid. To no surprise, the ANDA filers described the West Virginia opinion as “thorough and well-reasoned” and argued that collateral estoppel actually prevented the Delaware Court from issuing its own decision regarding the ‘514 patent and the lack of written description defense.
Now what? The Delaware Court does not need to follow the opinion of the West Virginia court. The courts are both district courts which are at the same level. While the West Virginia decision can be persuasive, the Delaware Court is not bound to follow it. It can really do what it wants, either accepting the West Virginia decision or ignoring it.
However, collateral estoppel is an important legal principle that has been around for centuries. The idea of it is simple: you get one chance to try your case. Collateral estoppel prevents a loser in a court case from trying the same case again in a different court. Of course, we’ll see how the Delaware District Court applies collateral estoppel to this situation. After all, this situation has a slight twist here – Biogen has already tried this case twice. It set a hearing on the issue for August 11.
Some PIV history
These competing PIV cases are not unique. Three different district courts issued decisions in PIV cases involving Norvasc®(amlodipine). There have been others. In addition, there have been several situations where PIV cases compete with decisions the Patent Trial and Appeal Board issue in Inter Partes Review proceedings. Mylan was involved in a prior IPR decision in this situation as well.
If you are wondering why Biogen sued Mylan in West Virginia and not in Delaware to avoid this pitfall, you can see why by reading this Quarterly Note (2Q 2018).